Primary care clinicians focus on acute migraine management, despite the chronic nature of this neurological disease.

Erenumab effectively induces Medication Overuse Headache remission in chronic migraine patients. Monthly 140 mg injections show significant benefits.

About The Study: In this study, monthly, 140 mg erenumab injections safely and effectively achieved medication overuse headaches remission in patients with nonopioid chronic migraine and ...

Erenumab is potentially efficacious in treating chronic flushing and erythema associated with rosacea, according to a study. “Rosacea is a common, chronic facial skin disease, often ...

Patients with migraine undergoing treatment with anti-CGRP receptor antibodies may be at risk for elevated systolic and diastolic blood pressure.

Erenumab significantly reduces the number of monthly migraine days and use of acute migraine-specific medication in patients with episodic or chronic migraine, regardless of aura status.

Migraine prevention drug erenumab (Aimovig) appeared safe and effective in patients both with and without aura, pooled trial data showed. In a post hoc secondary analysis of four randomized ...

In the phase 4 study, Aimovig (erenumab-aooe) had a lower discontinuation rate and superior efficacy in adults with migraine vs topiramate.

Real-world data collected from 5 US health centers highlight erenumab's efficacy in chronic migraineurs.

NICE is likely to recommend erenumab for preventing migraine in January 2021 after earlier drafts of the guidance were appealed.

The first randomized, double blind, head-to-head study of Aimovig ® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and ...

A new migraine drug that can halve the length of time sufferers are laid low by the debilitating condition has been hailed as an “incredibly important” advance. Erenumab, a laboratory-made ...